Importance of ALT levels of >30 in patients with MASLD: Nara Declaration 2023
-
- Kawanaka Miwa
- Department of General Internal Medicine 2, Kawasaki Medical Center, Kawasaki Medical School
-
- Fujii Hideki
- Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University
-
- Iwaki Michihiro
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine
-
- Hayashi Hideki
- Department of Gastroenterology and Hepatology, Gifu Municipal Hospital
-
- Toyoda Hidenori
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
-
- Oeda Satoshi
- Liver Center, Saga University Hospital
-
- Hyogo Hideyuki
- Hyogo Life Care Clinic
-
- Morishita Asahiro
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University
-
- Munekage Kensuke
- Department of Gastroenterology, Kochi Prefectural Hata Kenmin Hospital
-
- Kawata Kazuhito
- Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine
-
- Tsutsumi Tsubasa
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine
-
- Sawada Koji
- Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University
-
- Maeshiro Tatsuji
- Department of Gastroenterology, Urasoe General Hospital
-
- Tobita Hiroshi
- Department of Hepatology, Shimane University Hospital
-
- Yoshida Yuichi
- Department of Gastroenterology and Hepatology, Suita Municipal Hospital
-
- Naito Masafumi
- Department of Gastroenterology and Hepatology, Suita Municipal Hospital
-
- Araki Asuka
- Division of Pathology, Shimane University Hospital
-
- Arakaki Shingo
- First Department of Internal Medicine, University of the Ryukyus Hospital
-
- Kawaguchi Takumi
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine
-
- Noritake Hidenao
- Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine
-
- Ono Masafumi
- Division of Innovative Medicine for Hepatobiliary & Pancreatology, Faculty of Medicine, Kagawa University
-
- Masaki Tsutomu
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University
-
- Yasuda Satoshi
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital
-
- Tomita Eiichi
- Department of Gastroenterology and Hepatology, Gifu Municipal Hospital
-
- Yoneda Masato
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine
-
- Tokushige Akihiro
- Department of Clinical Pharmacology and Therapeutics School of Medicine, University of the Ryukyus
-
- Kamada Yoshihiro
- Department of Advanced Metabolic Hepatology, Osaka University, Graduate School of Medicine
-
- Takahashi Hirokazu
- Liver Center, Saga University Hospital
-
- Ueda Shinichiro
- Department of Clinical Pharmacology and Therapeutics School of Medicine, University of the Ryukyus
-
- Aishima Shinichi
- Department of Scientific Pathology Graduate School of Medical Sciences, Kyushu University
-
- Sumida Yoshio
- Graduate School of Healthcare Management, International University of Healthcare and Welfare
-
- Okanoue Takeshi
- Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital
-
- Nakajima Atsushi
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine
Bibliographic Information
- Other Title
-
- 奈良宣言(ALT over 30)のMASLD(metabolic dysfunction-associated steatotic liver disease)における臨床的意義の検証
- ナラ センゲン(ALT over 30)ノ MASLD (metabolic dysfunction-associated steatotic liver disease)ニ オケル リンショウテキ イギ ノ ケンショウ
Search this article
Description
<p>The Nara Declaration 2023 recommends that patients with ALT levels of >30 U/L and those who have steatosis, diabetes, hypertension, and/or dyslipidemia should be referred to a hepatologist, considering the results of the FIB4 index and/or platelet count. ALT levels of >30 U/L is a simple and useful indicator and, when combined with the FIB4 index and platelet count, can detect MASLD cases that require further treatment and follow-up. Moreover, among patients with MAFLD and ALT levels of ≤30 U/L, the FIB4 index may be useful for identifying those at risk of MASLD. The Nara Declaration 2023 is an important and convenient guideline that provides primary care doctors with specific indications for referral to a hepatologist. When combined with the FIB4 index, ALT levels of >30 U/L is expected to predict high-risk MASLD cases.</p>
Journal
-
- Kanzo
-
Kanzo 65 (4), 186-191, 2024-04-01
The Japan Society of Hepatology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390581235165654144
-
- NII Book ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL BIB ID
- 033443985
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
- OpenAIRE
-
- Abstract License Flag
- Disallowed